{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FoundationOne+Liquid+CDx",
    "query": {
      "intervention": "FoundationOne Liquid CDx"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 6,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T01:55:34.758Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04712877",
      "title": "Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "NSCLC"
      ],
      "interventions": [
        {
          "name": "ctDNA, tumor NGS",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Lung Cancer Mutation Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1000,
      "start_date": "2022-06-15",
      "completion_date": "2026-06-15",
      "has_results": false,
      "last_update_posted_date": "2024-07-17",
      "last_synced_at": "2026-09-03T01:55:34.758Z",
      "location_count": 21,
      "location_summary": "Davis, California • Los Angeles, California • Orange, California + 13 more",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04712877"
    },
    {
      "nct_id": "NCT06065748",
      "title": "A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Giredestrant",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "LHRH Agonist",
          "type": "DRUG"
        },
        {
          "name": "FoundationOne Liquid CDx Assay (F1LCDx)",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1050,
      "start_date": "2023-12-11",
      "completion_date": "2029-02-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-05",
      "last_synced_at": "2026-09-03T01:55:34.758Z",
      "location_count": 61,
      "location_summary": "Daphne, Alabama • Auburn, California • Glendale, California + 54 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Auburn",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Harbor City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06065748"
    },
    {
      "nct_id": "NCT05272423",
      "title": "Studying Pathways of Resistance in KRAS-driven Cancers",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "KRAS P.G12C"
      ],
      "interventions": [
        {
          "name": "FoundationOne® Liquid CDx",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Addario Lung Cancer Medical Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2022-09-08",
      "completion_date": "2026-04-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-09-03T01:55:34.758Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05272423"
    },
    {
      "nct_id": "NCT06068075",
      "title": "Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ewing Sarcoma",
        "Ewing Sarcoma of Bone",
        "Ewing Sarcoma of Soft Tissue",
        "Peripheral Primitive Neuroectodermal Tumor",
        "Peripheral Primitive Neuroectodermal Tumor of Bone",
        "Peripheral Primitive Neuroectodermal Tumor of Soft Tissue",
        "High-grade Osteosarcoma"
      ],
      "interventions": [
        {
          "name": "FoundationOne Liquid CDx",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "12 Months to 50 Years"
      },
      "enrollment_count": 340,
      "start_date": "2018-05-08",
      "completion_date": "2027-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-09-03T01:55:34.758Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06068075"
    },
    {
      "nct_id": "NCT04504604",
      "title": "TCF-001 TRACK (Target Rare Cancer Knowledge) Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Rare Cancers",
        "Cholangiocarcinoma",
        "Cancer of Unknown Primary Site"
      ],
      "interventions": [
        {
          "name": "FoundationOne CDx and FoundationOne Liquid CDx",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "TargetCancer Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2020-10-01",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-09-03T01:55:34.758Z",
      "location_count": 1,
      "location_summary": "Cambridge, Massachusetts",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04504604"
    },
    {
      "nct_id": "NCT04929223",
      "title": "A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Inavolisib",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Tiragolumab",
          "type": "DRUG"
        },
        {
          "name": "SY-5609",
          "type": "DRUG"
        },
        {
          "name": "Divarasib",
          "type": "DRUG"
        },
        {
          "name": "FOLFOX",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI",
          "type": "DRUG"
        },
        {
          "name": "FoundationOne®Liquid CDx",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 542,
      "start_date": "2021-10-22",
      "completion_date": "2030-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-09-03T01:55:34.758Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04929223"
    }
  ]
}